CS1 in Phase II for the treatment of PAH
CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for PAH. CS1 targets the root cause of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries. The goal of CS1's development is to improve quality of life and extend survival for patients with PAH.
CS014 in Phase I for the treatment of IPF
The investigational drug candidate CS014, in phase I development, belongs to Cereno’s HDAC inhibitor program, capitalizing on the principle of epigenetic modulation. CS014 is a new chemical entity with a multi-modal mechanism of action as an epigenetic modulator, under development for Idiopathic Pulmonary Fibrosis (IPF).
CS585 in preclinical phase
Drug candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.